nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—STAT5B—hematologic cancer	0.0712	0.193	CbGaD
Dasatinib—BTK—hematologic cancer	0.0348	0.0943	CbGaD
Dasatinib—TXK—hematologic cancer	0.0348	0.0943	CbGaD
Dasatinib—ABL2—hematologic cancer	0.031	0.0841	CbGaD
Dasatinib—LCK—hematologic cancer	0.0296	0.0802	CbGaD
Dasatinib—FGR—hematologic cancer	0.0263	0.0715	CbGaD
Dasatinib—MAPK14—hematologic cancer	0.0263	0.0715	CbGaD
Dasatinib—JAK2—hematologic cancer	0.02	0.0542	CbGaD
Dasatinib—CSF1R—hematologic cancer	0.0178	0.0483	CbGaD
Dasatinib—PDGFRB—hematologic cancer	0.0155	0.0421	CbGaD
Dasatinib—PDGFRA—hematologic cancer	0.0151	0.0411	CbGaD
Dasatinib—HCK—Nilotinib—hematologic cancer	0.0147	0.0406	CbGbCtD
Dasatinib—EPHB3—Nilotinib—hematologic cancer	0.0147	0.0406	CbGbCtD
Dasatinib—EPHB2—Nilotinib—hematologic cancer	0.0147	0.0406	CbGbCtD
Dasatinib—ABL1—hematologic cancer	0.0138	0.0376	CbGaD
Dasatinib—BTK—Mitoxantrone—hematologic cancer	0.0128	0.0355	CbGbCtD
Dasatinib—SRC—hematologic cancer	0.0125	0.034	CbGaD
Dasatinib—JAK2—Ruxolitinib—hematologic cancer	0.0121	0.0334	CbGbCtD
Dasatinib—EPHA4—Nilotinib—hematologic cancer	0.0117	0.0323	CbGbCtD
Dasatinib—EPHB4—Nilotinib—hematologic cancer	0.0117	0.0323	CbGbCtD
Dasatinib—EPHA3—Nilotinib—hematologic cancer	0.0117	0.0323	CbGbCtD
Dasatinib—FRK—Nilotinib—hematologic cancer	0.0117	0.0323	CbGbCtD
Dasatinib—MAPK14—Nilotinib—hematologic cancer	0.0117	0.0323	CbGbCtD
Dasatinib—KIT—hematologic cancer	0.0111	0.0301	CbGaD
Dasatinib—MAP3K3—Ruxolitinib—hematologic cancer	0.0101	0.028	CbGbCtD
Dasatinib—EPHA8—Nilotinib—hematologic cancer	0.00978	0.027	CbGbCtD
Dasatinib—EPHA2—Nilotinib—hematologic cancer	0.00978	0.027	CbGbCtD
Dasatinib—MAP3K2—Ruxolitinib—hematologic cancer	0.00876	0.0242	CbGbCtD
Dasatinib—FGR—Nilotinib—hematologic cancer	0.00845	0.0233	CbGbCtD
Dasatinib—LYN—Nilotinib—hematologic cancer	0.00747	0.0206	CbGbCtD
Dasatinib—BLK—Nilotinib—hematologic cancer	0.00747	0.0206	CbGbCtD
Dasatinib—EPHB6—Nilotinib—hematologic cancer	0.00747	0.0206	CbGbCtD
Dasatinib—ABL2—Imatinib—hematologic cancer	0.00739	0.0204	CbGbCtD
Dasatinib—KIT—Imatinib—hematologic cancer	0.00739	0.0204	CbGbCtD
Dasatinib—CSF1R—Imatinib—hematologic cancer	0.00739	0.0204	CbGbCtD
Dasatinib—PDGFRA—Imatinib—hematologic cancer	0.00739	0.0204	CbGbCtD
Dasatinib—LCK—Imatinib—hematologic cancer	0.00673	0.0186	CbGbCtD
Dasatinib—PDGFRB—Imatinib—hematologic cancer	0.00673	0.0186	CbGbCtD
Dasatinib—CSF1R—Nilotinib—hematologic cancer	0.00672	0.0185	CbGbCtD
Dasatinib—PDGFRA—Nilotinib—hematologic cancer	0.00672	0.0185	CbGbCtD
Dasatinib—ABL2—Nilotinib—hematologic cancer	0.00672	0.0185	CbGbCtD
Dasatinib—KIT—Nilotinib—hematologic cancer	0.00672	0.0185	CbGbCtD
Dasatinib—CYP1B1—Procarbazine—hematologic cancer	0.00625	0.0172	CbGbCtD
Dasatinib—ABCG2—hematologic cancer	0.00615	0.0167	CbGaD
Dasatinib—PDGFRB—Nilotinib—hematologic cancer	0.00611	0.0169	CbGbCtD
Dasatinib—LCK—Nilotinib—hematologic cancer	0.00611	0.0169	CbGbCtD
Dasatinib—MAP2K5—Nilotinib—hematologic cancer	0.00611	0.0169	CbGbCtD
Dasatinib—MAP3K19—Ruxolitinib—hematologic cancer	0.00582	0.0161	CbGbCtD
Dasatinib—ABL1—Imatinib—hematologic cancer	0.00534	0.0147	CbGbCtD
Dasatinib—ABL1—Nilotinib—hematologic cancer	0.00486	0.0134	CbGbCtD
Dasatinib—CYP1B1—Daunorubicin—hematologic cancer	0.00335	0.00925	CbGbCtD
Dasatinib—ABCG2—Clofarabine—hematologic cancer	0.00272	0.0075	CbGbCtD
Dasatinib—ABCB1—hematologic cancer	0.00256	0.00694	CbGaD
Dasatinib—CYP1B1—Mitoxantrone—hematologic cancer	0.00204	0.00562	CbGbCtD
Dasatinib—CYP1A2—Anagrelide—hematologic cancer	0.00162	0.00446	CbGbCtD
Dasatinib—CYP1A1—Methoxsalen—hematologic cancer	0.00162	0.00446	CbGbCtD
Dasatinib—ABCG2—Daunorubicin—hematologic cancer	0.00159	0.0044	CbGbCtD
Dasatinib—CYP1A1—Bortezomib—hematologic cancer	0.00154	0.00424	CbGbCtD
Dasatinib—CYP1A1—Daunorubicin—hematologic cancer	0.00147	0.00406	CbGbCtD
Dasatinib—ABCG2—Teniposide—hematologic cancer	0.00138	0.00382	CbGbCtD
Dasatinib—CYP1A1—Thalidomide—hematologic cancer	0.00134	0.0037	CbGbCtD
Dasatinib—ABCG2—Cladribine—hematologic cancer	0.00133	0.00366	CbGbCtD
Dasatinib—ABCG2—Imatinib—hematologic cancer	0.00122	0.00337	CbGbCtD
Dasatinib—CYP1A1—Dacarbazine—hematologic cancer	0.00115	0.00318	CbGbCtD
Dasatinib—ABCG2—Nilotinib—hematologic cancer	0.00111	0.00306	CbGbCtD
Dasatinib—CYP1B1—Dexamethasone—hematologic cancer	0.00106	0.00291	CbGbCtD
Dasatinib—ABCB1—Lenalidomide—hematologic cancer	0.00098	0.0027	CbGbCtD
Dasatinib—ABCG2—Mitoxantrone—hematologic cancer	0.000968	0.00267	CbGbCtD
Dasatinib—CYP3A5—Daunorubicin—hematologic cancer	0.000883	0.00244	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—hematologic cancer	0.000876	0.00242	CbGbCtD
Dasatinib—CYP1A2—Carmustine—hematologic cancer	0.000849	0.00234	CbGbCtD
Dasatinib—CYP3A5—Thalidomide—hematologic cancer	0.000804	0.00222	CbGbCtD
Dasatinib—CYP3A5—Teniposide—hematologic cancer	0.000767	0.00212	CbGbCtD
Dasatinib—ABCG2—Irinotecan—hematologic cancer	0.000762	0.0021	CbGbCtD
Dasatinib—CYP1A2—Methoxsalen—hematologic cancer	0.000722	0.00199	CbGbCtD
Dasatinib—CYP3A5—Ifosfamide—hematologic cancer	0.000708	0.00195	CbGbCtD
Dasatinib—CYP1A2—Bortezomib—hematologic cancer	0.000687	0.0019	CbGbCtD
Dasatinib—CYP3A5—Imatinib—hematologic cancer	0.000676	0.00187	CbGbCtD
Dasatinib—ABCG2—Vincristine—hematologic cancer	0.000666	0.00184	CbGbCtD
Dasatinib—CYP1A2—Daunorubicin—hematologic cancer	0.000657	0.00181	CbGbCtD
Dasatinib—CYP1A2—Alitretinoin—hematologic cancer	0.000644	0.00178	CbGbCtD
Dasatinib—ABCG2—Cisplatin—hematologic cancer	0.000621	0.00171	CbGbCtD
Dasatinib—ABCG2—Etoposide—hematologic cancer	0.00061	0.00168	CbGbCtD
Dasatinib—CYP1A2—Thalidomide—hematologic cancer	0.000598	0.00165	CbGbCtD
Dasatinib—CYP3A4—Bexarotene—hematologic cancer	0.000587	0.00162	CbGbCtD
Dasatinib—ABCB1—Daunorubicin—hematologic cancer	0.000574	0.00159	CbGbCtD
Dasatinib—ABCB1—Alitretinoin—hematologic cancer	0.000563	0.00155	CbGbCtD
Dasatinib—CYP3A4—Lomustine—hematologic cancer	0.000546	0.00151	CbGbCtD
Dasatinib—CYP3A4—Busulfan—hematologic cancer	0.000546	0.00151	CbGbCtD
Dasatinib—CYP1A2—Dacarbazine—hematologic cancer	0.000514	0.00142	CbGbCtD
Dasatinib—CYP1A2—Imatinib—hematologic cancer	0.000503	0.00139	CbGbCtD
Dasatinib—ABCG2—Dexamethasone—hematologic cancer	0.000502	0.00139	CbGbCtD
Dasatinib—CYP3A4—Thiotepa—hematologic cancer	0.000486	0.00134	CbGbCtD
Dasatinib—CYP1A1—Dexamethasone—hematologic cancer	0.000463	0.00128	CbGbCtD
Dasatinib—ABCB1—Imatinib—hematologic cancer	0.00044	0.00121	CbGbCtD
Dasatinib—CYP3A5—Irinotecan—hematologic cancer	0.000422	0.00117	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—hematologic cancer	0.000416	0.00115	CbGbCtD
Dasatinib—ABCG2—Methotrexate—hematologic cancer	0.000403	0.00111	CbGbCtD
Dasatinib—ABCB1—Nilotinib—hematologic cancer	0.0004	0.0011	CbGbCtD
Dasatinib—ABCB1—Vinorelbine—hematologic cancer	0.000396	0.00109	CbGbCtD
Dasatinib—CYP3A4—Methoxsalen—hematologic cancer	0.000378	0.00104	CbGbCtD
Dasatinib—CYP3A5—Vincristine—hematologic cancer	0.000369	0.00102	CbGbCtD
Dasatinib—CYP3A4—Bortezomib—hematologic cancer	0.00036	0.000993	CbGbCtD
Dasatinib—ABCB1—Mitoxantrone—hematologic cancer	0.000349	0.000963	CbGbCtD
Dasatinib—CYP3A4—Daunorubicin—hematologic cancer	0.000344	0.00095	CbGbCtD
Dasatinib—CYP3A5—Etoposide—hematologic cancer	0.000338	0.000934	CbGbCtD
Dasatinib—ABCB1—Betamethasone—hematologic cancer	0.000311	0.000859	CbGbCtD
Dasatinib—ABCB1—Gemcitabine—hematologic cancer	0.000308	0.000851	CbGbCtD
Dasatinib—ABCB1—Prednisolone—hematologic cancer	0.000307	0.000847	CbGbCtD
Dasatinib—CYP3A4—Cytarabine—hematologic cancer	0.000304	0.000838	CbGbCtD
Dasatinib—CYP3A4—Teniposide—hematologic cancer	0.000299	0.000825	CbGbCtD
Dasatinib—ABCB1—Prednisone—hematologic cancer	0.00029	0.0008	CbGbCtD
Dasatinib—CYP3A5—Dexamethasone—hematologic cancer	0.000278	0.000767	CbGbCtD
Dasatinib—CYP3A4—Ifosfamide—hematologic cancer	0.000276	0.000762	CbGbCtD
Dasatinib—ABCB1—Irinotecan—hematologic cancer	0.000275	0.000759	CbGbCtD
Dasatinib—STAT5B—blood—hematologic cancer	0.000272	0.00543	CbGeAlD
Dasatinib—BMX—lung—hematologic cancer	0.000269	0.00537	CbGeAlD
Dasatinib—CYP3A4—Imatinib—hematologic cancer	0.000264	0.000728	CbGbCtD
Dasatinib—STAT5B—bone marrow—hematologic cancer	0.000264	0.00525	CbGeAlD
Dasatinib—FRK—testis—hematologic cancer	0.00026	0.00519	CbGeAlD
Dasatinib—PKMYT1—testis—hematologic cancer	0.00026	0.00519	CbGeAlD
Dasatinib—RIPK2—hematopoietic system—hematologic cancer	0.000258	0.00515	CbGeAlD
Dasatinib—SRMS—lung—hematologic cancer	0.000258	0.00513	CbGeAlD
Dasatinib—TXK—lung—hematologic cancer	0.000255	0.00508	CbGeAlD
Dasatinib—PTK6—lung—hematologic cancer	0.000252	0.00503	CbGeAlD
Dasatinib—SIK1—hematopoietic system—hematologic cancer	0.000252	0.00502	CbGeAlD
Dasatinib—CYP1A2—Etoposide—hematologic cancer	0.000252	0.000695	CbGbCtD
Dasatinib—CYP3A4—Ruxolitinib—hematologic cancer	0.000248	0.000685	CbGbCtD
Dasatinib—ERBB3—hematopoietic system—hematologic cancer	0.000247	0.00492	CbGeAlD
Dasatinib—MAP3K2—hematopoietic system—hematologic cancer	0.000245	0.00488	CbGeAlD
Dasatinib—ABCB1—Vinblastine—hematologic cancer	0.000244	0.000674	CbGbCtD
Dasatinib—TXK—testis—hematologic cancer	0.000241	0.00479	CbGeAlD
Dasatinib—ABCB1—Vincristine—hematologic cancer	0.00024	0.000663	CbGbCtD
Dasatinib—CYP3A4—Nilotinib—hematologic cancer	0.00024	0.000661	CbGbCtD
Dasatinib—STAT5B—lung—hematologic cancer	0.000239	0.00476	CbGeAlD
Dasatinib—EPHA8—testis—hematologic cancer	0.000238	0.00475	CbGeAlD
Dasatinib—CYP3A4—Vinorelbine—hematologic cancer	0.000238	0.000656	CbGbCtD
Dasatinib—TESK1—gonad—hematologic cancer	0.000231	0.0046	CbGeAlD
Dasatinib—MAPK14—hematopoietic system—hematologic cancer	0.00023	0.00459	CbGeAlD
Dasatinib—FGR—hematopoietic system—hematologic cancer	0.000229	0.00457	CbGeAlD
Dasatinib—ZAK—blood—hematologic cancer	0.000228	0.00454	CbGeAlD
Dasatinib—STK36—gonad—hematologic cancer	0.000227	0.00453	CbGeAlD
Dasatinib—STAT5B—testis—hematologic cancer	0.000225	0.00449	CbGeAlD
Dasatinib—ABCB1—Cisplatin—hematologic cancer	0.000224	0.000618	CbGbCtD
Dasatinib—LYN—blood—hematologic cancer	0.000222	0.00442	CbGeAlD
Dasatinib—EPHA3—lung—hematologic cancer	0.000221	0.0044	CbGeAlD
Dasatinib—ABCB1—Etoposide—hematologic cancer	0.00022	0.000608	CbGbCtD
Dasatinib—LIMK2—gonad—hematologic cancer	0.00022	0.00438	CbGeAlD
Dasatinib—EPHB1—lymph node—hematologic cancer	0.000219	0.00437	CbGeAlD
Dasatinib—EPHB4—hematopoietic system—hematologic cancer	0.000218	0.00435	CbGeAlD
Dasatinib—CYP3A4—Triamcinolone—hematologic cancer	0.000217	0.0006	CbGbCtD
Dasatinib—BTK—blood—hematologic cancer	0.000217	0.00433	CbGeAlD
Dasatinib—JAK2—hematopoietic system—hematologic cancer	0.000217	0.00432	CbGeAlD
Dasatinib—SIK3—lung—hematologic cancer	0.000215	0.00428	CbGeAlD
Dasatinib—EPHA2—hematopoietic system—hematologic cancer	0.000214	0.00426	CbGeAlD
Dasatinib—FYN—hematopoietic system—hematologic cancer	0.000214	0.00426	CbGeAlD
Dasatinib—STK35—gonad—hematologic cancer	0.000213	0.00424	CbGeAlD
Dasatinib—CSK—gonad—hematologic cancer	0.000212	0.00422	CbGeAlD
Dasatinib—BTK—bone marrow—hematologic cancer	0.00021	0.00419	CbGeAlD
Dasatinib—CYP3A4—Mitoxantrone—hematologic cancer	0.000209	0.000577	CbGbCtD
Dasatinib—MAP3K3—hematopoietic system—hematologic cancer	0.000209	0.00416	CbGeAlD
Dasatinib—MAP4K5—hematopoietic system—hematologic cancer	0.000209	0.00416	CbGeAlD
Dasatinib—EPHA3—testis—hematologic cancer	0.000208	0.00415	CbGeAlD
Dasatinib—SIK3—testis—hematologic cancer	0.000203	0.00404	CbGeAlD
Dasatinib—TESK1—blood—hematologic cancer	0.000201	0.00401	CbGeAlD
Dasatinib—ZAK—lung—hematologic cancer	0.0002	0.00398	CbGeAlD
Dasatinib—STK36—blood—hematologic cancer	0.000198	0.00395	CbGeAlD
Dasatinib—YES1—hematopoietic system—hematologic cancer	0.000193	0.00384	CbGeAlD
Dasatinib—SIK1—gonad—hematologic cancer	0.000192	0.00382	CbGeAlD
Dasatinib—LIMK2—blood—hematologic cancer	0.000191	0.00381	CbGeAlD
Dasatinib—MAP3K19—lung—hematologic cancer	0.000191	0.00381	CbGeAlD
Dasatinib—BMPR1B—lung—hematologic cancer	0.000191	0.00381	CbGeAlD
Dasatinib—BTK—lung—hematologic cancer	0.00019	0.00379	CbGeAlD
Dasatinib—EPHA4—gonad—hematologic cancer	0.00019	0.00378	CbGeAlD
Dasatinib—PDGFRA—hematopoietic system—hematologic cancer	0.000189	0.00377	CbGeAlD
Dasatinib—ZAK—testis—hematologic cancer	0.000188	0.00375	CbGeAlD
Dasatinib—TNK2—lung—hematologic cancer	0.000188	0.00374	CbGeAlD
Dasatinib—CYP3A4—Betamethasone—hematologic cancer	0.000186	0.000514	CbGbCtD
Dasatinib—MAP3K2—gonad—hematologic cancer	0.000186	0.00371	CbGeAlD
Dasatinib—SRC—hematopoietic system—hematologic cancer	0.000186	0.0037	CbGeAlD
Dasatinib—CSK—blood—hematologic cancer	0.000184	0.00367	CbGeAlD
Dasatinib—BMX—lymph node—hematologic cancer	0.000184	0.00367	CbGeAlD
Dasatinib—CYP3A4—Prednisolone—hematologic cancer	0.000184	0.000508	CbGbCtD
Dasatinib—BLK—lymph node—hematologic cancer	0.000182	0.00363	CbGeAlD
Dasatinib—HCK—blood—hematologic cancer	0.000182	0.00363	CbGeAlD
Dasatinib—ABCB1—Dexamethasone—hematologic cancer	0.000181	0.0005	CbGbCtD
Dasatinib—ABL2—blood—hematologic cancer	0.000181	0.0036	CbGeAlD
Dasatinib—MAP3K19—testis—hematologic cancer	0.000181	0.0036	CbGeAlD
Dasatinib—BMPR1B—testis—hematologic cancer	0.000181	0.0036	CbGeAlD
Dasatinib—BTK—testis—hematologic cancer	0.00018	0.00358	CbGeAlD
Dasatinib—CSK—bone marrow—hematologic cancer	0.000178	0.00355	CbGeAlD
Dasatinib—TNK2—testis—hematologic cancer	0.000177	0.00353	CbGeAlD
Dasatinib—TESK1—lung—hematologic cancer	0.000176	0.00351	CbGeAlD
Dasatinib—HCK—bone marrow—hematologic cancer	0.000176	0.00351	CbGeAlD
Dasatinib—TXK—lymph node—hematologic cancer	0.000174	0.00348	CbGeAlD
Dasatinib—CYP3A4—Prednisone—hematologic cancer	0.000174	0.000479	CbGbCtD
Dasatinib—EPHB3—lung—hematologic cancer	0.000174	0.00346	CbGeAlD
Dasatinib—STK36—lung—hematologic cancer	0.000174	0.00346	CbGeAlD
Dasatinib—RIPK2—blood—hematologic cancer	0.000171	0.00341	CbGeAlD
Dasatinib—LIMK2—lung—hematologic cancer	0.000168	0.00334	CbGeAlD
Dasatinib—SIK1—blood—hematologic cancer	0.000167	0.00333	CbGeAlD
Dasatinib—CSF1R—hematopoietic system—hematologic cancer	0.000167	0.00332	CbGeAlD
Dasatinib—TESK1—testis—hematologic cancer	0.000166	0.00332	CbGeAlD
Dasatinib—RIPK2—bone marrow—hematologic cancer	0.000166	0.0033	CbGeAlD
Dasatinib—EPHA4—blood—hematologic cancer	0.000165	0.0033	CbGeAlD
Dasatinib—JAK2—gonad—hematologic cancer	0.000165	0.00328	CbGeAlD
Dasatinib—CYP3A4—Irinotecan—hematologic cancer	0.000165	0.000454	CbGbCtD
Dasatinib—STK36—testis—hematologic cancer	0.000164	0.00326	CbGeAlD
Dasatinib—EPHB3—testis—hematologic cancer	0.000164	0.00326	CbGeAlD
Dasatinib—STAT5B—lymph node—hematologic cancer	0.000163	0.00325	CbGeAlD
Dasatinib—STK35—lung—hematologic cancer	0.000163	0.00324	CbGeAlD
Dasatinib—MAP3K2—blood—hematologic cancer	0.000162	0.00323	CbGeAlD
Dasatinib—SIK1—bone marrow—hematologic cancer	0.000162	0.00322	CbGeAlD
Dasatinib—CSK—lung—hematologic cancer	0.000162	0.00322	CbGeAlD
Dasatinib—HCK—lung—hematologic cancer	0.00016	0.00318	CbGeAlD
Dasatinib—MAP3K3—gonad—hematologic cancer	0.000159	0.00316	CbGeAlD
Dasatinib—MAP4K5—gonad—hematologic cancer	0.000159	0.00316	CbGeAlD
Dasatinib—ABL2—lung—hematologic cancer	0.000159	0.00316	CbGeAlD
Dasatinib—LIMK2—testis—hematologic cancer	0.000158	0.00316	CbGeAlD
Dasatinib—MAP3K2—bone marrow—hematologic cancer	0.000157	0.00313	CbGeAlD
Dasatinib—STK35—testis—hematologic cancer	0.000154	0.00306	CbGeAlD
Dasatinib—MAPK14—blood—hematologic cancer	0.000153	0.00304	CbGeAlD
Dasatinib—CSK—testis—hematologic cancer	0.000153	0.00304	CbGeAlD
Dasatinib—FGR—blood—hematologic cancer	0.000152	0.00303	CbGeAlD
Dasatinib—LCK—blood—hematologic cancer	0.000152	0.00303	CbGeAlD
Dasatinib—KIT—hematopoietic system—hematologic cancer	0.000151	0.00301	CbGeAlD
Dasatinib—EPHA3—lymph node—hematologic cancer	0.000151	0.00301	CbGeAlD
Dasatinib—HCK—testis—hematologic cancer	0.000151	0.003	CbGeAlD
Dasatinib—ABCB1—Doxorubicin—hematologic cancer	0.00015	0.000414	CbGbCtD
Dasatinib—RIPK2—lung—hematologic cancer	0.00015	0.00299	CbGeAlD
Dasatinib—ABL2—testis—hematologic cancer	0.00015	0.00298	CbGeAlD
Dasatinib—PDGFRB—hematopoietic system—hematologic cancer	0.000148	0.00294	CbGeAlD
Dasatinib—MAPK14—bone marrow—hematologic cancer	0.000148	0.00294	CbGeAlD
Dasatinib—FGR—bone marrow—hematologic cancer	0.000147	0.00293	CbGeAlD
Dasatinib—LCK—bone marrow—hematologic cancer	0.000147	0.00293	CbGeAlD
Dasatinib—SIK3—lymph node—hematologic cancer	0.000147	0.00292	CbGeAlD
Dasatinib—YES1—gonad—hematologic cancer	0.000147	0.00292	CbGeAlD
Dasatinib—SIK1—lung—hematologic cancer	0.000146	0.00292	CbGeAlD
Dasatinib—CYP3A4—Vinblastine—hematologic cancer	0.000146	0.000404	CbGbCtD
Dasatinib—ABCB1—Methotrexate—hematologic cancer	0.000145	0.000401	CbGbCtD
Dasatinib—EPHA4—lung—hematologic cancer	0.000145	0.00289	CbGeAlD
Dasatinib—EPHB4—blood—hematologic cancer	0.000145	0.00288	CbGeAlD
Dasatinib—CYP3A4—Vincristine—hematologic cancer	0.000144	0.000397	CbGbCtD
Dasatinib—PDGFRA—gonad—hematologic cancer	0.000144	0.00287	CbGeAlD
Dasatinib—ERBB3—lung—hematologic cancer	0.000144	0.00286	CbGeAlD
Dasatinib—JAK2—blood—hematologic cancer	0.000144	0.00286	CbGeAlD
Dasatinib—MAP3K2—lung—hematologic cancer	0.000142	0.00283	CbGeAlD
Dasatinib—EPHA2—blood—hematologic cancer	0.000142	0.00283	CbGeAlD
Dasatinib—FYN—blood—hematologic cancer	0.000142	0.00282	CbGeAlD
Dasatinib—RIPK2—testis—hematologic cancer	0.000142	0.00282	CbGeAlD
Dasatinib—SRC—gonad—hematologic cancer	0.000141	0.00281	CbGeAlD
Dasatinib—EPHB4—bone marrow—hematologic cancer	0.00014	0.00279	CbGeAlD
Dasatinib—JAK2—bone marrow—hematologic cancer	0.000139	0.00277	CbGeAlD
Dasatinib—MAP4K5—blood—hematologic cancer	0.000138	0.00276	CbGeAlD
Dasatinib—MAP3K3—blood—hematologic cancer	0.000138	0.00276	CbGeAlD
Dasatinib—SIK1—testis—hematologic cancer	0.000138	0.00275	CbGeAlD
Dasatinib—FYN—bone marrow—hematologic cancer	0.000137	0.00273	CbGeAlD
Dasatinib—EPHA4—testis—hematologic cancer	0.000137	0.00273	CbGeAlD
Dasatinib—ZAK—lymph node—hematologic cancer	0.000137	0.00272	CbGeAlD
Dasatinib—ERBB3—testis—hematologic cancer	0.000135	0.0027	CbGeAlD
Dasatinib—MAP3K2—testis—hematologic cancer	0.000134	0.00267	CbGeAlD
Dasatinib—MAP4K5—bone marrow—hematologic cancer	0.000134	0.00267	CbGeAlD
Dasatinib—MAP3K3—bone marrow—hematologic cancer	0.000134	0.00267	CbGeAlD
Dasatinib—MAPK14—lung—hematologic cancer	0.000134	0.00266	CbGeAlD
Dasatinib—FGR—lung—hematologic cancer	0.000133	0.00265	CbGeAlD
Dasatinib—LCK—lung—hematologic cancer	0.000133	0.00265	CbGeAlD
Dasatinib—EPHB6—blood—hematologic cancer	0.000132	0.00263	CbGeAlD
Dasatinib—CYP3A4—Etoposide—hematologic cancer	0.000132	0.000364	CbGbCtD
Dasatinib—ABL1—hematopoietic system—hematologic cancer	0.000132	0.00262	CbGeAlD
Dasatinib—BMPR1B—lymph node—hematologic cancer	0.000131	0.00261	CbGeAlD
Dasatinib—BTK—lymph node—hematologic cancer	0.00013	0.00259	CbGeAlD
Dasatinib—FMO3—lung—hematologic cancer	0.000129	0.00256	CbGeAlD
Dasatinib—TNK2—lymph node—hematologic cancer	0.000128	0.00256	CbGeAlD
Dasatinib—YES1—blood—hematologic cancer	0.000128	0.00255	CbGeAlD
Dasatinib—EPHB4—lung—hematologic cancer	0.000127	0.00253	CbGeAlD
Dasatinib—CSF1R—gonad—hematologic cancer	0.000127	0.00252	CbGeAlD
Dasatinib—MAPK14—testis—hematologic cancer	0.000126	0.00251	CbGeAlD
Dasatinib—JAK2—lung—hematologic cancer	0.000126	0.00251	CbGeAlD
Dasatinib—LCK—testis—hematologic cancer	0.000126	0.0025	CbGeAlD
Dasatinib—FGR—testis—hematologic cancer	0.000126	0.0025	CbGeAlD
Dasatinib—PDGFRA—blood—hematologic cancer	0.000125	0.0025	CbGeAlD
Dasatinib—EPHA2—lung—hematologic cancer	0.000124	0.00248	CbGeAlD
Dasatinib—FYN—lung—hematologic cancer	0.000124	0.00247	CbGeAlD
Dasatinib—YES1—bone marrow—hematologic cancer	0.000124	0.00246	CbGeAlD
Dasatinib—SRC—blood—hematologic cancer	0.000123	0.00245	CbGeAlD
Dasatinib—FMO3—testis—hematologic cancer	0.000121	0.00242	CbGeAlD
Dasatinib—MAP3K3—lung—hematologic cancer	0.000121	0.00242	CbGeAlD
Dasatinib—MAP4K5—lung—hematologic cancer	0.000121	0.00242	CbGeAlD
Dasatinib—TESK1—lymph node—hematologic cancer	0.000121	0.0024	CbGeAlD
Dasatinib—EPHB4—testis—hematologic cancer	0.00012	0.00238	CbGeAlD
Dasatinib—JAK2—testis—hematologic cancer	0.000119	0.00237	CbGeAlD
Dasatinib—EPHB3—lymph node—hematologic cancer	0.000119	0.00237	CbGeAlD
Dasatinib—STK36—lymph node—hematologic cancer	0.000119	0.00237	CbGeAlD
Dasatinib—EPHA2—testis—hematologic cancer	0.000117	0.00234	CbGeAlD
Dasatinib—FYN—testis—hematologic cancer	0.000117	0.00233	CbGeAlD
Dasatinib—EPHB6—lung—hematologic cancer	0.000116	0.00231	CbGeAlD
Dasatinib—KIT—gonad—hematologic cancer	0.000115	0.00229	CbGeAlD
Dasatinib—LIMK2—lymph node—hematologic cancer	0.000115	0.00229	CbGeAlD
Dasatinib—MAP4K5—testis—hematologic cancer	0.000114	0.00228	CbGeAlD
Dasatinib—MAP3K3—testis—hematologic cancer	0.000114	0.00228	CbGeAlD
Dasatinib—MAP2K5—blood—hematologic cancer	0.000113	0.00225	CbGeAlD
Dasatinib—PDGFRB—gonad—hematologic cancer	0.000112	0.00224	CbGeAlD
Dasatinib—YES1—lung—hematologic cancer	0.000112	0.00223	CbGeAlD
Dasatinib—CYP1B1—hematopoietic system—hematologic cancer	0.000112	0.00222	CbGeAlD
Dasatinib—STK35—lymph node—hematologic cancer	0.000111	0.00222	CbGeAlD
Dasatinib—CSK—lymph node—hematologic cancer	0.000111	0.0022	CbGeAlD
Dasatinib—CSF1R—blood—hematologic cancer	0.00011	0.0022	CbGeAlD
Dasatinib—PDGFRA—lung—hematologic cancer	0.00011	0.00219	CbGeAlD
Dasatinib—EPHB6—testis—hematologic cancer	0.000109	0.00218	CbGeAlD
Dasatinib—HCK—lymph node—hematologic cancer	0.000109	0.00217	CbGeAlD
Dasatinib—ABL2—lymph node—hematologic cancer	0.000108	0.00216	CbGeAlD
Dasatinib—CYP3A4—Dexamethasone—hematologic cancer	0.000108	0.000299	CbGbCtD
Dasatinib—SRC—lung—hematologic cancer	0.000108	0.00215	CbGeAlD
Dasatinib—CSF1R—bone marrow—hematologic cancer	0.000107	0.00213	CbGeAlD
Dasatinib—YES1—testis—hematologic cancer	0.000106	0.00211	CbGeAlD
Dasatinib—PDGFRA—testis—hematologic cancer	0.000104	0.00207	CbGeAlD
Dasatinib—ERBB3—Podofilox—Teniposide—hematologic cancer	0.000103	0.066	CbGdCrCtD
Dasatinib—RIPK2—lymph node—hematologic cancer	0.000103	0.00204	CbGeAlD
Dasatinib—SRC—testis—hematologic cancer	0.000102	0.00203	CbGeAlD
Dasatinib—KIT—blood—hematologic cancer	0.0001	0.002	CbGeAlD
Dasatinib—SIK1—lymph node—hematologic cancer	0.0001	0.002	CbGeAlD
Dasatinib—ABL1—gonad—hematologic cancer	0.0001	0.00199	CbGeAlD
Dasatinib—EPHA4—lymph node—hematologic cancer	9.92e-05	0.00198	CbGeAlD
Dasatinib—MAP2K5—lung—hematologic cancer	9.91e-05	0.00198	CbGeAlD
Dasatinib—ERBB3—lymph node—hematologic cancer	9.82e-05	0.00196	CbGeAlD
Dasatinib—PDGFRB—blood—hematologic cancer	9.79e-05	0.00195	CbGeAlD
Dasatinib—MAP3K2—lymph node—hematologic cancer	9.73e-05	0.00194	CbGeAlD
Dasatinib—KIT—bone marrow—hematologic cancer	9.7e-05	0.00193	CbGeAlD
Dasatinib—CSF1R—lung—hematologic cancer	9.68e-05	0.00193	CbGeAlD
Dasatinib—PDGFRB—bone marrow—hematologic cancer	9.47e-05	0.00189	CbGeAlD
Dasatinib—MAP2K5—testis—hematologic cancer	9.35e-05	0.00186	CbGeAlD
Dasatinib—MAPK14—lymph node—hematologic cancer	9.14e-05	0.00182	CbGeAlD
Dasatinib—CSF1R—testis—hematologic cancer	9.13e-05	0.00182	CbGeAlD
Dasatinib—FGR—lymph node—hematologic cancer	9.11e-05	0.00181	CbGeAlD
Dasatinib—LCK—lymph node—hematologic cancer	9.11e-05	0.00181	CbGeAlD
Dasatinib—CYP3A4—Doxorubicin—hematologic cancer	9e-05	0.000248	CbGbCtD
Dasatinib—FMO3—lymph node—hematologic cancer	8.8e-05	0.00175	CbGeAlD
Dasatinib—ABL1—Topotecan—Irinotecan—hematologic cancer	8.79e-05	0.0561	CbGdCrCtD
Dasatinib—KIT—lung—hematologic cancer	8.79e-05	0.00175	CbGeAlD
Dasatinib—ABL1—blood—hematologic cancer	8.72e-05	0.00174	CbGeAlD
Dasatinib—EPHB4—lymph node—hematologic cancer	8.67e-05	0.00173	CbGeAlD
Dasatinib—JAK2—lymph node—hematologic cancer	8.61e-05	0.00171	CbGeAlD
Dasatinib—PDGFRB—lung—hematologic cancer	8.58e-05	0.00171	CbGeAlD
Dasatinib—EPHA2—lymph node—hematologic cancer	8.5e-05	0.00169	CbGeAlD
Dasatinib—CSK—Epirubicin—Daunorubicin—hematologic cancer	8.5e-05	0.0543	CbGdCrCtD
Dasatinib—CSK—Doxorubicin—Daunorubicin—hematologic cancer	8.5e-05	0.0543	CbGdCrCtD
Dasatinib—FYN—lymph node—hematologic cancer	8.49e-05	0.00169	CbGeAlD
Dasatinib—CYP1B1—gonad—hematologic cancer	8.48e-05	0.00169	CbGeAlD
Dasatinib—ABL1—bone marrow—hematologic cancer	8.44e-05	0.00168	CbGeAlD
Dasatinib—MAP4K5—lymph node—hematologic cancer	8.3e-05	0.00165	CbGeAlD
Dasatinib—MAP3K3—lymph node—hematologic cancer	8.3e-05	0.00165	CbGeAlD
Dasatinib—KIT—testis—hematologic cancer	8.29e-05	0.00165	CbGeAlD
Dasatinib—PDGFRB—testis—hematologic cancer	8.1e-05	0.00161	CbGeAlD
Dasatinib—CYP1A2—hematopoietic system—hematologic cancer	7.99e-05	0.00159	CbGeAlD
Dasatinib—EPHB6—lymph node—hematologic cancer	7.93e-05	0.00158	CbGeAlD
Dasatinib—CYP1A1—hematopoietic system—hematologic cancer	7.88e-05	0.00157	CbGeAlD
Dasatinib—CYP3A5—hematopoietic system—hematologic cancer	7.71e-05	0.00154	CbGeAlD
Dasatinib—YES1—lymph node—hematologic cancer	7.66e-05	0.00153	CbGeAlD
Dasatinib—ABL1—lung—hematologic cancer	7.65e-05	0.00152	CbGeAlD
Dasatinib—PDGFRA—lymph node—hematologic cancer	7.52e-05	0.0015	CbGeAlD
Dasatinib—CYP1B1—blood—hematologic cancer	7.39e-05	0.00147	CbGeAlD
Dasatinib—SRC—lymph node—hematologic cancer	7.37e-05	0.00147	CbGeAlD
Dasatinib—CSK—Menadione—Thalidomide—hematologic cancer	7.23e-05	0.0461	CbGdCrCtD
Dasatinib—ABL1—testis—hematologic cancer	7.22e-05	0.00144	CbGeAlD
Dasatinib—MAP2K5—lymph node—hematologic cancer	6.78e-05	0.00135	CbGeAlD
Dasatinib—CSF1R—lymph node—hematologic cancer	6.62e-05	0.00132	CbGeAlD
Dasatinib—CYP1B1—lung—hematologic cancer	6.48e-05	0.00129	CbGeAlD
Dasatinib—CSK—Daunorubicin—Idarubicin—hematologic cancer	6.44e-05	0.0411	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Idarubicin—hematologic cancer	6.44e-05	0.0411	CbGdCrCtD
Dasatinib—CSK—Doxorubicin—Idarubicin—hematologic cancer	6.44e-05	0.0411	CbGdCrCtD
Dasatinib—ERBB3—Podofilox—Etoposide—hematologic cancer	6.15e-05	0.0392	CbGdCrCtD
Dasatinib—CYP1B1—testis—hematologic cancer	6.11e-05	0.00122	CbGeAlD
Dasatinib—KIT—lymph node—hematologic cancer	6.01e-05	0.0012	CbGeAlD
Dasatinib—ABL1—Doxorubicin—Daunorubicin—hematologic cancer	5.94e-05	0.0379	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Daunorubicin—hematologic cancer	5.94e-05	0.0379	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Daunorubicin—hematologic cancer	5.94e-05	0.0379	CbGdCrCtD
Dasatinib—PDGFRB—lymph node—hematologic cancer	5.87e-05	0.00117	CbGeAlD
Dasatinib—CYP3A4—hematopoietic system—hematologic cancer	5.78e-05	0.00115	CbGeAlD
Dasatinib—ABCG2—blood—hematologic cancer	5.5e-05	0.0011	CbGeAlD
Dasatinib—ABCG2—bone marrow—hematologic cancer	5.32e-05	0.00106	CbGeAlD
Dasatinib—CYP1A2—blood—hematologic cancer	5.3e-05	0.00105	CbGeAlD
Dasatinib—ERBB3—Vinblastine—Vinorelbine—hematologic cancer	5.29e-05	0.0338	CbGdCrCtD
Dasatinib—ABL1—lymph node—hematologic cancer	5.23e-05	0.00104	CbGeAlD
Dasatinib—CYP1A1—blood—hematologic cancer	5.22e-05	0.00104	CbGeAlD
Dasatinib—CYP3A5—blood—hematologic cancer	5.11e-05	0.00102	CbGeAlD
Dasatinib—ABCG2—lung—hematologic cancer	4.82e-05	0.000961	CbGeAlD
Dasatinib—CYP1A2—lung—hematologic cancer	4.64e-05	0.000925	CbGeAlD
Dasatinib—CYP1A1—lung—hematologic cancer	4.58e-05	0.000912	CbGeAlD
Dasatinib—ABCG2—testis—hematologic cancer	4.55e-05	0.000907	CbGeAlD
Dasatinib—ABL1—Epirubicin—Idarubicin—hematologic cancer	4.5e-05	0.0287	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Idarubicin—hematologic cancer	4.5e-05	0.0287	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Idarubicin—hematologic cancer	4.5e-05	0.0287	CbGdCrCtD
Dasatinib—CYP3A5—lung—hematologic cancer	4.48e-05	0.000892	CbGeAlD
Dasatinib—CYP1B1—lymph node—hematologic cancer	4.43e-05	0.000882	CbGeAlD
Dasatinib—ERBB3—Vinblastine—Vincristine—hematologic cancer	4.23e-05	0.027	CbGdCrCtD
Dasatinib—ABCB1—hematopoietic system—hematologic cancer	4.09e-05	0.000816	CbGeAlD
Dasatinib—CYP3A4—blood—hematologic cancer	3.83e-05	0.000764	CbGeAlD
Dasatinib—ABCG2—lymph node—hematologic cancer	3.3e-05	0.000657	CbGeAlD
Dasatinib—CYP1A1—lymph node—hematologic cancer	3.13e-05	0.000624	CbGeAlD
Dasatinib—ABCB1—gonad—hematologic cancer	3.11e-05	0.00062	CbGeAlD
Dasatinib—CSK—Doxorubicin—Epirubicin—hematologic cancer	2.96e-05	0.0189	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—hematologic cancer	2.96e-05	0.0189	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Betamethasone—hematologic cancer	2.81e-05	0.018	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Dexamethasone—hematologic cancer	2.81e-05	0.018	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Triamcinolone—hematologic cancer	2.75e-05	0.0175	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Doxorubicin—hematologic cancer	2.74e-05	0.0175	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—hematologic cancer	2.74e-05	0.0175	CbGdCrCtD
Dasatinib—ABCB1—blood—hematologic cancer	2.71e-05	0.00054	CbGeAlD
Dasatinib—ABCB1—bone marrow—hematologic cancer	2.63e-05	0.000523	CbGeAlD
Dasatinib—EPHB2—Diflorasone—Prednisone—hematologic cancer	2.61e-05	0.0167	CbGdCrCtD
Dasatinib—EPHB2—Diflorasone—Prednisolone—hematologic cancer	2.55e-05	0.0163	CbGdCrCtD
Dasatinib—ABCB1—lung—hematologic cancer	2.38e-05	0.000474	CbGeAlD
Dasatinib—ABCB1—testis—hematologic cancer	2.24e-05	0.000447	CbGeAlD
Dasatinib—ABL1—Daunorubicin—Epirubicin—hematologic cancer	2.07e-05	0.0132	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—hematologic cancer	2.07e-05	0.0132	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Epirubicin—hematologic cancer	2.07e-05	0.0132	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—hematologic cancer	1.91e-05	0.0122	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Doxorubicin—hematologic cancer	1.91e-05	0.0122	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—hematologic cancer	1.91e-05	0.0122	CbGdCrCtD
Dasatinib—ABCB1—lymph node—hematologic cancer	1.63e-05	0.000324	CbGeAlD
Dasatinib—PKMYT1—Danazol—Prednisone—hematologic cancer	1.48e-05	0.00945	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Dexamethasone—hematologic cancer	1.14e-05	0.0073	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Betamethasone—hematologic cancer	1.14e-05	0.0073	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Triamcinolone—hematologic cancer	1.12e-05	0.00713	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Triamcinolone—hematologic cancer	1.12e-05	0.00713	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Prednisone—hematologic cancer	1.06e-05	0.00677	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Prednisone—hematologic cancer	1.06e-05	0.00677	CbGdCrCtD
Dasatinib—TESK1—Dexamethasone—Prednisolone—hematologic cancer	1.04e-05	0.00661	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Prednisolone—hematologic cancer	1.04e-05	0.00661	CbGdCrCtD
Dasatinib—Alopecia—Epirubicin—hematologic cancer	5e-06	4.51e-05	CcSEcCtD
Dasatinib—Skin disorder—Prednisone—hematologic cancer	4.99e-06	4.5e-05	CcSEcCtD
Dasatinib—Nausea—Gemcitabine—hematologic cancer	4.99e-06	4.5e-05	CcSEcCtD
Dasatinib—Vomiting—Cisplatin—hematologic cancer	4.98e-06	4.49e-05	CcSEcCtD
Dasatinib—Hyperhidrosis—Prednisone—hematologic cancer	4.97e-06	4.48e-05	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—hematologic cancer	4.96e-06	4.47e-05	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—hematologic cancer	4.96e-06	4.47e-05	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—hematologic cancer	4.95e-06	4.46e-05	CcSEcCtD
Dasatinib—Rash—Cisplatin—hematologic cancer	4.94e-06	4.45e-05	CcSEcCtD
Dasatinib—Dermatitis—Cisplatin—hematologic cancer	4.93e-06	4.45e-05	CcSEcCtD
Dasatinib—Erythema—Epirubicin—hematologic cancer	4.93e-06	4.44e-05	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—hematologic cancer	4.93e-06	4.44e-05	CcSEcCtD
Dasatinib—Diarrhoea—Etoposide—hematologic cancer	4.91e-06	4.42e-05	CcSEcCtD
Dasatinib—Anorexia—Prednisone—hematologic cancer	4.9e-06	4.42e-05	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—hematologic cancer	4.89e-06	4.41e-05	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—hematologic cancer	4.88e-06	4.4e-05	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—hematologic cancer	4.88e-06	4.4e-05	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—hematologic cancer	4.87e-06	4.39e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Betamethasone—hematologic cancer	4.86e-06	4.39e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Dexamethasone—hematologic cancer	4.86e-06	4.39e-05	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—hematologic cancer	4.86e-06	4.38e-05	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—hematologic cancer	4.86e-06	4.38e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.83e-06	4.35e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Betamethasone—hematologic cancer	4.83e-06	4.35e-05	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—hematologic cancer	4.82e-06	4.35e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Triamcinolone—hematologic cancer	4.79e-06	4.32e-05	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—hematologic cancer	4.75e-06	4.28e-05	CcSEcCtD
Dasatinib—Malaise—Methotrexate—hematologic cancer	4.75e-06	4.28e-05	CcSEcCtD
Dasatinib—Dizziness—Etoposide—hematologic cancer	4.74e-06	4.28e-05	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—hematologic cancer	4.74e-06	4.27e-05	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—hematologic cancer	4.73e-06	4.26e-05	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—hematologic cancer	4.73e-06	4.26e-05	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—hematologic cancer	4.72e-06	4.25e-05	CcSEcCtD
Dasatinib—Chills—Doxorubicin—hematologic cancer	4.7e-06	4.24e-05	CcSEcCtD
Dasatinib—Urticaria—Dexamethasone—hematologic cancer	4.69e-06	4.23e-05	CcSEcCtD
Dasatinib—Urticaria—Betamethasone—hematologic cancer	4.69e-06	4.23e-05	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.68e-06	4.22e-05	CcSEcCtD
Dasatinib—Dizziness—Prednisolone—hematologic cancer	4.68e-06	4.22e-05	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—hematologic cancer	4.68e-06	4.22e-05	CcSEcCtD
Dasatinib—Asthenia—Triamcinolone—hematologic cancer	4.67e-06	4.21e-05	CcSEcCtD
Dasatinib—Body temperature increased—Betamethasone—hematologic cancer	4.67e-06	4.21e-05	CcSEcCtD
Dasatinib—Abdominal pain—Dexamethasone—hematologic cancer	4.67e-06	4.21e-05	CcSEcCtD
Dasatinib—Abdominal pain—Betamethasone—hematologic cancer	4.67e-06	4.21e-05	CcSEcCtD
Dasatinib—Body temperature increased—Dexamethasone—hematologic cancer	4.67e-06	4.21e-05	CcSEcCtD
Dasatinib—Nausea—Cisplatin—hematologic cancer	4.65e-06	4.19e-05	CcSEcCtD
Dasatinib—Insomnia—Prednisone—hematologic cancer	4.65e-06	4.19e-05	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—hematologic cancer	4.64e-06	4.19e-05	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—hematologic cancer	4.63e-06	4.17e-05	CcSEcCtD
Dasatinib—Pruritus—Triamcinolone—hematologic cancer	4.6e-06	4.15e-05	CcSEcCtD
Dasatinib—Cough—Methotrexate—hematologic cancer	4.59e-06	4.14e-05	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—hematologic cancer	4.59e-06	4.14e-05	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—hematologic cancer	4.57e-06	4.12e-05	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—hematologic cancer	4.56e-06	4.11e-05	CcSEcCtD
Dasatinib—Vomiting—Etoposide—hematologic cancer	4.56e-06	4.11e-05	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—hematologic cancer	4.56e-06	4.11e-05	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—hematologic cancer	4.56e-06	4.11e-05	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—hematologic cancer	4.55e-06	4.11e-05	CcSEcCtD
Dasatinib—Dyspepsia—Prednisone—hematologic cancer	4.53e-06	4.08e-05	CcSEcCtD
Dasatinib—Rash—Etoposide—hematologic cancer	4.52e-06	4.08e-05	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—hematologic cancer	4.52e-06	4.07e-05	CcSEcCtD
Dasatinib—Headache—Etoposide—hematologic cancer	4.49e-06	4.05e-05	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—hematologic cancer	4.48e-06	4.04e-05	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—hematologic cancer	4.48e-06	4.04e-05	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—hematologic cancer	4.48e-06	4.04e-05	CcSEcCtD
Dasatinib—Decreased appetite—Prednisone—hematologic cancer	4.47e-06	4.03e-05	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—hematologic cancer	4.46e-06	4.02e-05	CcSEcCtD
Dasatinib—Rash—Prednisolone—hematologic cancer	4.46e-06	4.02e-05	CcSEcCtD
Dasatinib—Dermatitis—Prednisolone—hematologic cancer	4.46e-06	4.02e-05	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.45e-06	4.01e-05	CcSEcCtD
Dasatinib—Malaise—Epirubicin—hematologic cancer	4.44e-06	4.01e-05	CcSEcCtD
Dasatinib—Fatigue—Prednisone—hematologic cancer	4.43e-06	4e-05	CcSEcCtD
Dasatinib—Headache—Prednisolone—hematologic cancer	4.43e-06	4e-05	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—hematologic cancer	4.43e-06	3.99e-05	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—hematologic cancer	4.43e-06	3.99e-05	CcSEcCtD
Dasatinib—Syncope—Epirubicin—hematologic cancer	4.42e-06	3.98e-05	CcSEcCtD
Dasatinib—Constipation—Prednisone—hematologic cancer	4.4e-06	3.96e-05	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—hematologic cancer	4.38e-06	3.95e-05	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—hematologic cancer	4.35e-06	3.93e-05	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—hematologic cancer	4.33e-06	3.91e-05	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—hematologic cancer	4.33e-06	3.9e-05	CcSEcCtD
Dasatinib—Dizziness—Triamcinolone—hematologic cancer	4.3e-06	3.88e-05	CcSEcCtD
Dasatinib—Cough—Epirubicin—hematologic cancer	4.3e-06	3.88e-05	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—hematologic cancer	4.3e-06	3.87e-05	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—hematologic cancer	4.27e-06	3.85e-05	CcSEcCtD
Dasatinib—Infection—Methotrexate—hematologic cancer	4.27e-06	3.85e-05	CcSEcCtD
Dasatinib—Nausea—Etoposide—hematologic cancer	4.26e-06	3.84e-05	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—hematologic cancer	4.25e-06	3.83e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Prednisone—hematologic cancer	4.24e-06	3.82e-05	CcSEcCtD
Dasatinib—Asthenia—Betamethasone—hematologic cancer	4.24e-06	3.82e-05	CcSEcCtD
Dasatinib—Asthenia—Dexamethasone—hematologic cancer	4.24e-06	3.82e-05	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—hematologic cancer	4.23e-06	3.81e-05	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—hematologic cancer	4.21e-06	3.8e-05	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—hematologic cancer	4.21e-06	3.8e-05	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—hematologic cancer	4.21e-06	3.79e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Prednisone—hematologic cancer	4.2e-06	3.79e-05	CcSEcCtD
Dasatinib—Nausea—Prednisolone—hematologic cancer	4.2e-06	3.79e-05	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—hematologic cancer	4.19e-06	3.78e-05	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—hematologic cancer	4.19e-06	3.78e-05	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—hematologic cancer	4.19e-06	3.78e-05	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—hematologic cancer	4.18e-06	3.77e-05	CcSEcCtD
Dasatinib—Pruritus—Dexamethasone—hematologic cancer	4.18e-06	3.77e-05	CcSEcCtD
Dasatinib—Pruritus—Betamethasone—hematologic cancer	4.18e-06	3.77e-05	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—hematologic cancer	4.17e-06	3.76e-05	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.17e-06	3.76e-05	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—hematologic cancer	4.15e-06	3.74e-05	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—hematologic cancer	4.14e-06	3.74e-05	CcSEcCtD
Dasatinib—Vomiting—Triamcinolone—hematologic cancer	4.14e-06	3.73e-05	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—hematologic cancer	4.11e-06	3.71e-05	CcSEcCtD
Dasatinib—Rash—Triamcinolone—hematologic cancer	4.1e-06	3.7e-05	CcSEcCtD
Dasatinib—Dermatitis—Triamcinolone—hematologic cancer	4.1e-06	3.69e-05	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—hematologic cancer	4.1e-06	3.69e-05	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—hematologic cancer	4.1e-06	3.69e-05	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—hematologic cancer	4.09e-06	3.69e-05	CcSEcCtD
Dasatinib—Urticaria—Prednisone—hematologic cancer	4.08e-06	3.68e-05	CcSEcCtD
Dasatinib—Headache—Triamcinolone—hematologic cancer	4.08e-06	3.67e-05	CcSEcCtD
Dasatinib—Abdominal pain—Prednisone—hematologic cancer	4.06e-06	3.66e-05	CcSEcCtD
Dasatinib—Body temperature increased—Prednisone—hematologic cancer	4.06e-06	3.66e-05	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—hematologic cancer	4.05e-06	3.66e-05	CcSEcCtD
Dasatinib—Diarrhoea—Betamethasone—hematologic cancer	4.04e-06	3.64e-05	CcSEcCtD
Dasatinib—Diarrhoea—Dexamethasone—hematologic cancer	4.04e-06	3.64e-05	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—hematologic cancer	4.03e-06	3.63e-05	CcSEcCtD
Dasatinib—Oedema—Epirubicin—hematologic cancer	4.02e-06	3.62e-05	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—hematologic cancer	4.01e-06	3.62e-05	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—hematologic cancer	4.01e-06	3.61e-05	CcSEcCtD
Dasatinib—Infection—Epirubicin—hematologic cancer	3.99e-06	3.6e-05	CcSEcCtD
Dasatinib—Cough—Doxorubicin—hematologic cancer	3.98e-06	3.59e-05	CcSEcCtD
Dasatinib—Shock—Epirubicin—hematologic cancer	3.96e-06	3.57e-05	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—hematologic cancer	3.95e-06	3.56e-05	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—hematologic cancer	3.94e-06	3.55e-05	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—hematologic cancer	3.94e-06	3.55e-05	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—hematologic cancer	3.94e-06	3.55e-05	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—hematologic cancer	3.92e-06	3.54e-05	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.91e-06	3.53e-05	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—hematologic cancer	3.91e-06	3.52e-05	CcSEcCtD
Dasatinib—Dizziness—Dexamethasone—hematologic cancer	3.9e-06	3.52e-05	CcSEcCtD
Dasatinib—Dizziness—Betamethasone—hematologic cancer	3.9e-06	3.52e-05	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—hematologic cancer	3.89e-06	3.5e-05	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—hematologic cancer	3.89e-06	3.5e-05	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—hematologic cancer	3.88e-06	3.5e-05	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—hematologic cancer	3.88e-06	3.5e-05	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—hematologic cancer	3.88e-06	3.5e-05	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—hematologic cancer	3.87e-06	3.49e-05	CcSEcCtD
Dasatinib—Nausea—Triamcinolone—hematologic cancer	3.86e-06	3.48e-05	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.85e-06	3.47e-05	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—hematologic cancer	3.83e-06	3.46e-05	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—hematologic cancer	3.83e-06	3.46e-05	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—hematologic cancer	3.83e-06	3.45e-05	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—hematologic cancer	3.82e-06	3.44e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Prednisone—hematologic cancer	3.79e-06	3.41e-05	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—hematologic cancer	3.78e-06	3.41e-05	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—hematologic cancer	3.76e-06	3.39e-05	CcSEcCtD
Dasatinib—Vomiting—Dexamethasone—hematologic cancer	3.75e-06	3.38e-05	CcSEcCtD
Dasatinib—Vomiting—Betamethasone—hematologic cancer	3.75e-06	3.38e-05	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—hematologic cancer	3.75e-06	3.38e-05	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—hematologic cancer	3.73e-06	3.37e-05	CcSEcCtD
Dasatinib—Rash—Dexamethasone—hematologic cancer	3.72e-06	3.36e-05	CcSEcCtD
Dasatinib—Rash—Betamethasone—hematologic cancer	3.72e-06	3.36e-05	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—hematologic cancer	3.72e-06	3.35e-05	CcSEcCtD
Dasatinib—Dermatitis—Dexamethasone—hematologic cancer	3.72e-06	3.35e-05	CcSEcCtD
Dasatinib—Dermatitis—Betamethasone—hematologic cancer	3.72e-06	3.35e-05	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.71e-06	3.34e-05	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—hematologic cancer	3.7e-06	3.34e-05	CcSEcCtD
Dasatinib—Headache—Betamethasone—hematologic cancer	3.7e-06	3.33e-05	CcSEcCtD
Dasatinib—Headache—Dexamethasone—hematologic cancer	3.7e-06	3.33e-05	CcSEcCtD
Dasatinib—Infection—Doxorubicin—hematologic cancer	3.7e-06	3.33e-05	CcSEcCtD
Dasatinib—Asthenia—Prednisone—hematologic cancer	3.69e-06	3.33e-05	CcSEcCtD
Dasatinib—Pain—Methotrexate—hematologic cancer	3.67e-06	3.31e-05	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.66e-06	3.3e-05	CcSEcCtD
Dasatinib—Shock—Doxorubicin—hematologic cancer	3.66e-06	3.3e-05	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—hematologic cancer	3.65e-06	3.29e-05	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—hematologic cancer	3.64e-06	3.28e-05	CcSEcCtD
Dasatinib—Pruritus—Prednisone—hematologic cancer	3.64e-06	3.28e-05	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—hematologic cancer	3.64e-06	3.28e-05	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—hematologic cancer	3.63e-06	3.27e-05	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—hematologic cancer	3.61e-06	3.26e-05	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—hematologic cancer	3.6e-06	3.24e-05	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—hematologic cancer	3.58e-06	3.23e-05	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—hematologic cancer	3.57e-06	3.22e-05	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—hematologic cancer	3.55e-06	3.2e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—hematologic cancer	3.54e-06	3.19e-05	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—hematologic cancer	3.54e-06	3.19e-05	CcSEcCtD
Dasatinib—Diarrhoea—Prednisone—hematologic cancer	3.52e-06	3.17e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—hematologic cancer	3.51e-06	3.17e-05	CcSEcCtD
Dasatinib—Nausea—Dexamethasone—hematologic cancer	3.51e-06	3.16e-05	CcSEcCtD
Dasatinib—Nausea—Betamethasone—hematologic cancer	3.51e-06	3.16e-05	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—hematologic cancer	3.5e-06	3.15e-05	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—hematologic cancer	3.48e-06	3.13e-05	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.47e-06	3.13e-05	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—hematologic cancer	3.47e-06	3.13e-05	CcSEcCtD
Dasatinib—Constipation—Epirubicin—hematologic cancer	3.44e-06	3.1e-05	CcSEcCtD
Dasatinib—Pain—Epirubicin—hematologic cancer	3.44e-06	3.1e-05	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—hematologic cancer	3.41e-06	3.08e-05	CcSEcCtD
Dasatinib—Dizziness—Prednisone—hematologic cancer	3.4e-06	3.06e-05	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—hematologic cancer	3.4e-06	3.06e-05	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—hematologic cancer	3.4e-06	3.06e-05	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.39e-06	3.06e-05	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—hematologic cancer	3.36e-06	3.03e-05	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—hematologic cancer	3.32e-06	2.99e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—hematologic cancer	3.31e-06	2.99e-05	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—hematologic cancer	3.31e-06	2.98e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—hematologic cancer	3.29e-06	2.96e-05	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—hematologic cancer	3.27e-06	2.95e-05	CcSEcCtD
Dasatinib—Vomiting—Prednisone—hematologic cancer	3.27e-06	2.95e-05	CcSEcCtD
Dasatinib—Rash—Prednisone—hematologic cancer	3.24e-06	2.92e-05	CcSEcCtD
Dasatinib—Dermatitis—Prednisone—hematologic cancer	3.24e-06	2.92e-05	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—hematologic cancer	3.23e-06	2.92e-05	CcSEcCtD
Dasatinib—Headache—Prednisone—hematologic cancer	3.22e-06	2.9e-05	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.21e-06	2.9e-05	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—hematologic cancer	3.21e-06	2.89e-05	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—hematologic cancer	3.19e-06	2.88e-05	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—hematologic cancer	3.18e-06	2.87e-05	CcSEcCtD
Dasatinib—Pain—Doxorubicin—hematologic cancer	3.18e-06	2.87e-05	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—hematologic cancer	3.18e-06	2.87e-05	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—hematologic cancer	3.18e-06	2.87e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—hematologic cancer	3.17e-06	2.85e-05	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—hematologic cancer	3.08e-06	2.78e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—hematologic cancer	3.07e-06	2.76e-05	CcSEcCtD
Dasatinib—Nausea—Prednisone—hematologic cancer	3.05e-06	2.75e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.04e-06	2.74e-05	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—hematologic cancer	3.04e-06	2.74e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—hematologic cancer	2.96e-06	2.67e-05	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—hematologic cancer	2.96e-06	2.66e-05	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—hematologic cancer	2.94e-06	2.65e-05	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—hematologic cancer	2.94e-06	2.65e-05	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—hematologic cancer	2.94e-06	2.65e-05	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—hematologic cancer	2.88e-06	2.6e-05	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—hematologic cancer	2.84e-06	2.56e-05	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—hematologic cancer	2.84e-06	2.56e-05	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—hematologic cancer	2.75e-06	2.48e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—hematologic cancer	2.74e-06	2.47e-05	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—hematologic cancer	2.73e-06	2.46e-05	CcSEcCtD
Dasatinib—Rash—Methotrexate—hematologic cancer	2.71e-06	2.44e-05	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—hematologic cancer	2.71e-06	2.44e-05	CcSEcCtD
Dasatinib—Headache—Methotrexate—hematologic cancer	2.69e-06	2.43e-05	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—hematologic cancer	2.67e-06	2.41e-05	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—hematologic cancer	2.66e-06	2.4e-05	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—hematologic cancer	2.63e-06	2.37e-05	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—hematologic cancer	2.56e-06	2.3e-05	CcSEcCtD
Dasatinib—Nausea—Methotrexate—hematologic cancer	2.55e-06	2.3e-05	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—hematologic cancer	2.55e-06	2.29e-05	CcSEcCtD
Dasatinib—Rash—Epirubicin—hematologic cancer	2.54e-06	2.29e-05	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—hematologic cancer	2.53e-06	2.28e-05	CcSEcCtD
Dasatinib—Headache—Epirubicin—hematologic cancer	2.52e-06	2.27e-05	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—hematologic cancer	2.46e-06	2.22e-05	CcSEcCtD
Dasatinib—Nausea—Epirubicin—hematologic cancer	2.39e-06	2.15e-05	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—hematologic cancer	2.37e-06	2.13e-05	CcSEcCtD
Dasatinib—Rash—Doxorubicin—hematologic cancer	2.35e-06	2.11e-05	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—hematologic cancer	2.34e-06	2.11e-05	CcSEcCtD
Dasatinib—Headache—Doxorubicin—hematologic cancer	2.33e-06	2.1e-05	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—hematologic cancer	2.21e-06	1.99e-05	CcSEcCtD
Dasatinib—JAK2—Signaling Pathways—CDKN1A—hematologic cancer	1.12e-07	1.05e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—hematologic cancer	1.12e-07	1.05e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—hematologic cancer	1.11e-07	1.05e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK8—hematologic cancer	1.11e-07	1.04e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SRC—hematologic cancer	1.11e-07	1.04e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—hematologic cancer	1.11e-07	1.04e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—hematologic cancer	1.1e-07	1.04e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—hematologic cancer	1.1e-07	1.03e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—hematologic cancer	1.1e-07	1.03e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF2—hematologic cancer	1.1e-07	1.03e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.1e-07	1.03e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—hematologic cancer	1.1e-07	1.03e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—hematologic cancer	1.1e-07	1.03e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—hematologic cancer	1.09e-07	1.03e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK8—hematologic cancer	1.09e-07	1.03e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—hematologic cancer	1.09e-07	1.03e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—hematologic cancer	1.09e-07	1.02e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—hematologic cancer	1.09e-07	1.02e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SRC—hematologic cancer	1.09e-07	1.02e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—hematologic cancer	1.09e-07	1.02e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—hematologic cancer	1.09e-07	1.02e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—hematologic cancer	1.09e-07	1.02e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—hematologic cancer	1.09e-07	1.02e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3R1—hematologic cancer	1.09e-07	1.02e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.08e-07	1.02e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—EP300—hematologic cancer	1.08e-07	1.01e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—hematologic cancer	1.08e-07	1.01e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EP300—hematologic cancer	1.08e-07	1.01e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CD—hematologic cancer	1.08e-07	1.01e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—hematologic cancer	1.08e-07	1.01e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CREBBP—hematologic cancer	1.07e-07	1.01e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—hematologic cancer	1.07e-07	1.01e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—hematologic cancer	1.07e-07	1e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—hematologic cancer	1.07e-07	1e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EP300—hematologic cancer	1.07e-07	1e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—hematologic cancer	1.06e-07	1e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—hematologic cancer	1.06e-07	9.99e-07	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—hematologic cancer	1.06e-07	9.99e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—hematologic cancer	1.06e-07	9.97e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—hematologic cancer	1.06e-07	9.96e-07	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—hematologic cancer	1.06e-07	9.94e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK3—hematologic cancer	1.06e-07	9.92e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JAK2—hematologic cancer	1.06e-07	9.91e-07	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—hematologic cancer	1.05e-07	9.86e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—hematologic cancer	1.05e-07	9.86e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SRC—hematologic cancer	1.05e-07	9.85e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—hematologic cancer	1.05e-07	9.84e-07	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—hematologic cancer	1.05e-07	9.84e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.05e-07	9.83e-07	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—hematologic cancer	1.05e-07	9.83e-07	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—hematologic cancer	1.04e-07	9.81e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK3—hematologic cancer	1.04e-07	9.78e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—hematologic cancer	1.04e-07	9.77e-07	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—hematologic cancer	1.04e-07	9.77e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—hematologic cancer	1.04e-07	9.76e-07	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—hematologic cancer	1.04e-07	9.75e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SRC—hematologic cancer	1.04e-07	9.72e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—hematologic cancer	1.03e-07	9.67e-07	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—hematologic cancer	1.03e-07	9.66e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—hematologic cancer	1.03e-07	9.65e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—hematologic cancer	1.03e-07	9.62e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.02e-07	9.62e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—hematologic cancer	1.02e-07	9.59e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK3—hematologic cancer	1.02e-07	9.57e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CD—hematologic cancer	1.02e-07	9.56e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.02e-07	9.56e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—hematologic cancer	1.01e-07	9.51e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—hematologic cancer	1.01e-07	9.51e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—hematologic cancer	1.01e-07	9.5e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JUN—hematologic cancer	1.01e-07	9.49e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—hematologic cancer	1.01e-07	9.49e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—hematologic cancer	1.01e-07	9.48e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—hematologic cancer	1.01e-07	9.47e-07	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—hematologic cancer	1.01e-07	9.47e-07	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—hematologic cancer	1.01e-07	9.47e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—hematologic cancer	1.01e-07	9.44e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK3—hematologic cancer	1e-07	9.42e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—hematologic cancer	1e-07	9.42e-07	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—hematologic cancer	1e-07	9.41e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MTOR—hematologic cancer	1e-07	9.41e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CB—hematologic cancer	1e-07	9.41e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CD44—hematologic cancer	1e-07	9.4e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NQO1—hematologic cancer	1e-07	9.4e-07	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—hematologic cancer	1e-07	9.39e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—hematologic cancer	9.99e-08	9.38e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—hematologic cancer	9.97e-08	9.35e-07	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—hematologic cancer	9.96e-08	9.35e-07	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—hematologic cancer	9.96e-08	9.35e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—hematologic cancer	9.95e-08	9.34e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NCOR1—hematologic cancer	9.95e-08	9.34e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—hematologic cancer	9.92e-08	9.31e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—hematologic cancer	9.9e-08	9.29e-07	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—hematologic cancer	9.88e-08	9.27e-07	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—hematologic cancer	9.86e-08	9.25e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—hematologic cancer	9.81e-08	9.2e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—hematologic cancer	9.78e-08	9.18e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—hematologic cancer	9.77e-08	9.17e-07	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—hematologic cancer	9.76e-08	9.16e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—hematologic cancer	9.74e-08	9.14e-07	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—hematologic cancer	9.67e-08	9.08e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK3—hematologic cancer	9.67e-08	9.08e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3R1—hematologic cancer	9.62e-08	9.03e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK8—hematologic cancer	9.57e-08	8.98e-07	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—hematologic cancer	9.55e-08	8.96e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK3—hematologic cancer	9.54e-08	8.96e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—hematologic cancer	9.5e-08	8.91e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYCS—hematologic cancer	9.48e-08	8.9e-07	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—hematologic cancer	9.45e-08	8.87e-07	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—hematologic cancer	9.45e-08	8.87e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	9.42e-08	8.84e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—hematologic cancer	9.41e-08	8.83e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—hematologic cancer	9.4e-08	8.83e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CB—hematologic cancer	9.4e-08	8.82e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—hematologic cancer	9.38e-08	8.81e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—hematologic cancer	9.36e-08	8.79e-07	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—hematologic cancer	9.33e-08	8.76e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EP300—hematologic cancer	9.33e-08	8.76e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—hematologic cancer	9.28e-08	8.71e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—hematologic cancer	9.26e-08	8.69e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—hematologic cancer	9.26e-08	8.69e-07	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—hematologic cancer	9.24e-08	8.67e-07	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—hematologic cancer	9.23e-08	8.66e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—hematologic cancer	9.22e-08	8.65e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—hematologic cancer	9.2e-08	8.64e-07	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—hematologic cancer	9.19e-08	8.63e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—hematologic cancer	9.17e-08	8.6e-07	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—hematologic cancer	9.12e-08	8.56e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SRC—hematologic cancer	9.07e-08	8.52e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—hematologic cancer	9.02e-08	8.47e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—hematologic cancer	8.97e-08	8.42e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JUN—hematologic cancer	8.95e-08	8.41e-07	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—hematologic cancer	8.93e-08	8.38e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CB—hematologic cancer	8.88e-08	8.33e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—hematologic cancer	8.84e-08	8.29e-07	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—hematologic cancer	8.83e-08	8.29e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—hematologic cancer	8.79e-08	8.25e-07	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—hematologic cancer	8.79e-08	8.25e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—hematologic cancer	8.75e-08	8.21e-07	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—hematologic cancer	8.74e-08	8.21e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—hematologic cancer	8.73e-08	8.19e-07	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—hematologic cancer	8.73e-08	8.19e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—hematologic cancer	8.73e-08	8.19e-07	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—hematologic cancer	8.72e-08	8.19e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—hematologic cancer	8.69e-08	8.16e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—hematologic cancer	8.68e-08	8.15e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—hematologic cancer	8.66e-08	8.13e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—hematologic cancer	8.6e-08	8.07e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CREBBP—hematologic cancer	8.58e-08	8.05e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—hematologic cancer	8.58e-08	8.05e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK8—hematologic cancer	8.47e-08	7.95e-07	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—hematologic cancer	8.45e-08	7.94e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—hematologic cancer	8.42e-08	7.9e-07	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—hematologic cancer	8.37e-08	7.86e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK3—hematologic cancer	8.36e-08	7.85e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—hematologic cancer	8.36e-08	7.84e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—hematologic cancer	8.32e-08	7.81e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—hematologic cancer	8.29e-08	7.78e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EP300—hematologic cancer	8.26e-08	7.75e-07	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—hematologic cancer	8.24e-08	7.73e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—hematologic cancer	8.15e-08	7.65e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CD—hematologic cancer	8.14e-08	7.64e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—hematologic cancer	8.13e-08	7.63e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—hematologic cancer	8.12e-08	7.62e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—hematologic cancer	8.11e-08	7.61e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—hematologic cancer	8.07e-08	7.58e-07	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—hematologic cancer	8.05e-08	7.56e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—hematologic cancer	8.03e-08	7.54e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—hematologic cancer	8.02e-08	7.53e-07	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—hematologic cancer	8e-08	7.51e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—hematologic cancer	7.98e-08	7.49e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—hematologic cancer	7.96e-08	7.47e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—hematologic cancer	7.91e-08	7.43e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—hematologic cancer	7.88e-08	7.4e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—hematologic cancer	7.82e-08	7.34e-07	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—hematologic cancer	7.8e-08	7.32e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—hematologic cancer	7.79e-08	7.31e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.75e-08	7.27e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—hematologic cancer	7.75e-08	7.27e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—EP300—hematologic cancer	7.74e-08	7.27e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—hematologic cancer	7.73e-08	7.25e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—hematologic cancer	7.73e-08	7.25e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—hematologic cancer	7.72e-08	7.25e-07	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—hematologic cancer	7.72e-08	7.25e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3R1—hematologic cancer	7.68e-08	7.21e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—hematologic cancer	7.68e-08	7.21e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NCOR1—hematologic cancer	7.68e-08	7.21e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—hematologic cancer	7.67e-08	7.2e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—hematologic cancer	7.67e-08	7.2e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—hematologic cancer	7.62e-08	7.16e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—hematologic cancer	7.62e-08	7.15e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—hematologic cancer	7.51e-08	7.05e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—hematologic cancer	7.46e-08	7e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK3—hematologic cancer	7.4e-08	6.95e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—hematologic cancer	7.39e-08	6.94e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—hematologic cancer	7.39e-08	6.93e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—hematologic cancer	7.34e-08	6.89e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—EP300—hematologic cancer	7.32e-08	6.87e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—hematologic cancer	7.29e-08	6.84e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—hematologic cancer	7.2e-08	6.76e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—hematologic cancer	7.18e-08	6.74e-07	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—hematologic cancer	7.18e-08	6.74e-07	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—hematologic cancer	7.13e-08	6.69e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CB—hematologic cancer	7.09e-08	6.66e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—hematologic cancer	7.07e-08	6.64e-07	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—hematologic cancer	7.03e-08	6.6e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—hematologic cancer	6.98e-08	6.55e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—hematologic cancer	6.9e-08	6.48e-07	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—hematologic cancer	6.88e-08	6.46e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CREBBP—hematologic cancer	6.85e-08	6.43e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—hematologic cancer	6.79e-08	6.37e-07	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—hematologic cancer	6.77e-08	6.36e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—hematologic cancer	6.68e-08	6.27e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—hematologic cancer	6.65e-08	6.24e-07	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—hematologic cancer	6.53e-08	6.13e-07	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—hematologic cancer	6.52e-08	6.12e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CD—hematologic cancer	6.5e-08	6.1e-07	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—hematologic cancer	6.44e-08	6.04e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—hematologic cancer	6.41e-08	6.02e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—hematologic cancer	6.39e-08	5.99e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3R1—hematologic cancer	6.13e-08	5.76e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—hematologic cancer	6.13e-08	5.75e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—hematologic cancer	6.11e-08	5.74e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—hematologic cancer	6.11e-08	5.74e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—hematologic cancer	5.91e-08	5.55e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—EP300—hematologic cancer	5.84e-08	5.49e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—hematologic cancer	5.73e-08	5.38e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	5.7e-08	5.35e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CB—hematologic cancer	5.66e-08	5.31e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—hematologic cancer	5.65e-08	5.31e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—hematologic cancer	5.64e-08	5.29e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—hematologic cancer	5.41e-08	5.08e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—hematologic cancer	5.41e-08	5.08e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CREBBP—hematologic cancer	5.29e-08	4.96e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.01e-08	4.71e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—hematologic cancer	4.99e-08	4.69e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—hematologic cancer	4.95e-08	4.65e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—hematologic cancer	4.89e-08	4.59e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	4.73e-08	4.44e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—hematologic cancer	4.68e-08	4.39e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—EP300—hematologic cancer	4.67e-08	4.38e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—hematologic cancer	4.42e-08	4.15e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	4.37e-08	4.1e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—hematologic cancer	4.32e-08	4.06e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—hematologic cancer	3.78e-08	3.54e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—EP300—hematologic cancer	3.6e-08	3.38e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—hematologic cancer	3.53e-08	3.32e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—hematologic cancer	3.45e-08	3.24e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—hematologic cancer	2.82e-08	2.65e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.66e-08	2.5e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—hematologic cancer	2.18e-08	2.04e-07	CbGpPWpGaD
